1. Volume 70, Issue 5, Pages 724-731 (November 2016)
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer 
Pasquale Rescigno, David Lorente, Diletta Bianchini, Roberta Ferraldeschi, Michael P. Kolinsky, Spyridon Sideris, Zafeiris Zafeiriou, Semini Sumanasuriya, Alan D. Smith, Niven Mehra, Anuradha Jayaram, Raquel Perez-Lopez, Joaquin Mateo, Chris Parker, David P. Dearnaley, Nina Tunariu, Alison Reid, Gerhardt Attard, Johann S. de Bono 
European Urology 
Volume 70, Issue 5, Pages (November 2016)
DOI: /j.eururo
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1
Kaplan-Meier curves for overall survival (OS) for a decrease in prostate-specific antigen of ≥30% at 4 wk as a dichotomous variable: (A) overall study population, (B) post-chemotherapy population, and (C) pre-chemotherapy population. CI=confidence interval; HR=hazard ratio calculated from Cox regression models.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions